(Q51970686)

19 April 2018

title

Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. (English)

1 reference

19 April 2018

1 reference

M C Irizarry

1

1 reference

19 April 2018

Y Yao

2

1 reference

19 April 2018

B T Hyman

3

1 reference

19 April 2018

J H Growdon

4

1 reference

19 April 2018

D Praticò

5

1 reference

19 April 2018

publication date

9 October 2007

1 reference

19 April 2018

Neurodegenerative Diseases

published in

1 reference

19 April 2018

volume

4

1 reference

19 April 2018

issue

6

1 reference

19 April 2018

page(s)

403-405

1 reference

19 April 2018

Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease

cites work

1 reference

Increased CSF F2-isoprostane concentration in probable AD.

21 January 2018

1 reference

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

21 January 2018

1 reference

Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease.

21 January 2018

1 reference

Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease

21 January 2018

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

21 January 2018

1 reference

Diagnostic criteria for Parkinson disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000107699

1 reference

19 April 2018

PubMed ID

17934322

1 reference

19 April 2018